

Special Issue

Implications of Antibiotics Use during the COVID-19 Pandemic: Present and Future

Message from the Guest Editor

The coronavirus disease 2019 (COVID-19) pandemic, caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), has had a global impact, leading to more than 120 million cases confirmed and more than 2.6 million deaths reported as of March 16, 2021. The implications on the management of patients including multiple aspects, such as the repurposing of antimicrobials, as in the case of antibiotics, but also the therapy of bacterial secondary infections and coinfections, have been matters of concern since the beginning of the pandemic. This Special Issue will present emerging concepts regarding the implications of antibiotics use during the COVID-19 pandemic, searching for further understanding of the current evidence and future scenarios.

Guest Editor

Prof. Dr. Alfonso J. Rodriguez-Morales

Grupo de Investigación Biomedicina, Faculty of Medicine, Fundacion Universitaria Autonoma de las Américas, Sede Pereira, Pereira, Risaralda, Colombia

Deadline for manuscript submissions

closed (31 May 2022)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/81650

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)